Medication Assisted Treatment (MAT) Training

Mi-CCSI, in partnership with the Michigan Opioid Collaborative (MOC) and the American Society of Addiction Medicine (ASAM), is hosting five sessions of the ASAM Treatment of Opioid Use Disorder course.  This course will provide the required eight (8) educational hours required to obtain the Medication Assisted Treatment (MAT) waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.

Intended Audience

Physicians and advance practice providers

Training Dates & Registration

Friday, June 14, 2019 | Marquette
Staybridge Suites Hotel
855 West Washington Street
Marquette, MI

June 14 Marquette MAT Training Registration


Jun Marquette MAT Training Flyer

Monday, June 3, 2019 | Ann Arbor
University of Michigan
Rachel Upjohn Building
4250 Plymouth Road
Ann Arbor, MI

June 3 Ann Arbor MAT Training Registration


June Ann Arbor MAT Training Flyer


Physicians are required to complete an eight-hour training to qualify for a waiver to prescribe and dispense Buprenorphine (Drug Addiction Treatment Act of 2000). This training is certified by ASAM through which physicians are able to obtain the learning requirements necessary to obtain the waiver. This 8-hour course covers treating opioid use disorder using interactive, case-based learning and evidence-based practices. This course will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

The training and after-training support will all be free of charge.

Learning Objectives

Upon completion of this educational activity participants should be able to:

  • Summarize the clinical pharmacology, efficacy, and safety of methadone, buprenorphine, and naltrexone in treating opioid use disorders
  • Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
  • Describe procedures for initiating, stabilizing, maintaining, monitoring, and modifying treatment of patients on buprenorphine or naltrexone
  • Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
  • Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

Payments for attendance

Scholarships are available for the first 15 providers registering for the training. These funds are intended to off-set loss time for attending the training. These scholarships are at a first-come-first-serve basis. and will be paid out as follows:
Physicians (MD, DO)—$500
Advanced practice providers (NP, PA)— $250

Post-training support

MOC will provide after-training assistance to any provider needing to access a resource to answer questions or to assist with difficult cases. This support will be provided free to providers.


Edward Jouney, DO, MS - University of Michigan: Clinical instructor, psychiatrist at UMATS and U of M's Back and Pain Center, Ann Arbor, MI
Cara Poland, MD - Spectrum Health: Lead addiction medicine physician, Grand Rapids, MI

*Faculty may change based on availability

Continuing Medical Education Credits

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.